Immunization against influenza in humans using an oral enteric-coated killed virus vaccine.
By ingestion of subunit-killed influenza virus vaccine in the form of enteric-coated capsules, local synthesis of secretory IgA (sIgA) antibody was stimulated in human nasal secretions. A fairly equal antibody response initiated by oral and intramuscular administration was demonstrated in the nasal secretions, although a systemic immune response was not elicited from ingestion of the vaccine. If the secretory antibody response resulted from absorption of antigen and transport to the respiratory mucosa, systemic (serum) antibody would be expected. Therefore these findings support the hypothesis that specialized collections of lymphoid cells in the small intestines have IgA precursor cells which circulate and populate distant mucosal sites. A number of studies have suggested that protection against mucosal infection by a variety of respiratory viruses correlates better with the presence and level of sIgA antibody than with serum antibody. The orally administered vaccine was associated with no more side effects than placebo, in contradistinction to the intramuscular route. Thus, the oral method of influenza vaccination could prove to be superior in providing for immunological protection due to equal secretory antibody stimulation, improved convenience and less toxicity.
D000284:Administration, Oral; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D002214:Capsules; D005260:Female; D006801:Humans; D007114:Immunization; D007071:Immunoglobulin A, Secretory / Q000032:analysis / Q000096:biosynthesis*; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D007273:Injections, Intramuscular; D008297:Male; D009297:Nasal Mucosa / Q000276:immunology* / Q000378:metabolism
D000914:Antibodies, Viral; D002214:Capsules; D007071:Immunoglobulin A, Secretory; D007252:Influenza Vaccines